Locus trial

Locus Biosciences announced it has opened enrollment for a Phase 1b clinical trial evaluating a CRISPR Cas3-enhanced phage (crPhage™) product that will target E. coli causing urinary tract infections. This is the world's first controlled clinical trial for a CRISPR-enhanced phage therapy.